Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review

Primary malignant melanoma of the lung is an extremely rare pulmonary carcinoma. Only 45 cases have been reported in the literature. Herein, we report a case of a 46‐year‐old male patient with an O Rh negative blood type who presented with pulmonary bronchial symptoms and underwent lobectomy. Genetic testing was also performed but no targetable mutations were found, and the patient's PD‐L1 RNA level was low. He developed brain metastasis four months after surgery and received radiotherapy but died 21 months after diagnosis. We review the published cases of this rare pulmonary lesion.

show abstract

“…and Kyriakopoulos et al . conducted systematic summaries in 1999 ( n = 20) and 2017 ( n = 41), respectively . Kyriakopoulos et al .…”

Section: Discussionmentioning

confidence: 99%

Primary pulmonary malignant melanoma: Case report and literature review

Shi

Zhu

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…The combination of pembrolizumab with RT has also shown longer progression-free survival and overall survival in patients with advanced non-small cell lung cancer (NSCLC) [24]. Interestingly, beyond NSCLC, there are 41 reported cases of primary pulmonary malignant melanomas in the literature in which patients were treated with pembrolizumab in adjuvant setting with chemotherapy ± RT [48]. Thus, pembrolizumab could be a more potent treatment option in future clinical studies.…”

Section: Discussionmentioning

confidence: 99%

The Combination of Radiotherapy with Pembrolizumab in the Treatment of Metastatic Melanoma Patients: a Systematic Review

Anahid

Afra

2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Melanoma is a severe form of skin cancer arising from melanocytes. In recent years, immunotherapy in particular, immune checkpoint inhibitor (ICI), has revolutionized the treatment of metastatic melanoma. Recent studies have explored the potential of treatment of metastatic melanoma using the combination of ICI with radiotherapy (RT). In present study, we systematically review available clinical studies involving the combination of RT with pembrolizumab. A systematic search using the electronic databases including PubMed, Scopus, and Embase was conducted to retrieve relevant clinical studies investigating the use of RT+ pembrolizumab on metastatic melanoma patients. Results showed that a total of 16 studies involving 612 metastatic melanoma patients were included. Furthermore, the treatment combination was generally safe with grade 3 or higher toxicities ranging from 1 to 11%. In conclusion, this therapeutic modality is promising. However, gray areas such as limited prospective studies and optimal timing will need to be addressed in future studies.

show abstract

“…Of the total cases, 21 of them did not receive any chemotherapy or radiation while 15 of them received chemotherapy as adjuvant and 4 of them received radiation. In regard to mortality, 26 of them died at various times after surgery, status of one patient was not reported, and remaining were alive at the various time frame after surgical resection [7]. …”

Section: Discussionmentioning

confidence: 99%

Primary malignant melanoma of the lung: a case report of a rare tumor and review of the literature

Yünce

Selinger

Krimsky

et al. 2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Primary malignant melanoma of the lung (PMML) is a rare malignancy that exhibits aggressive behavior and has a very poor prognosis. We are reporting on a case of PMML in an otherwise healthy 22-year-old Caucasian male with no significant past medical history and an unremarkable family history. The patient initially presented with a 2-month history of a cough and an unexplained 22-lb weight loss. His initial chest X-ray demonstrated opacification of the right lower lobe (RLL) of his lung and a subsequent computerized tomography scan (CT scan) of his lung revealed a large mass occupying most of his RLL (Figure 1). The patient subsequently underwent a bronchoscopy with endobronchial ultrasound. Biopsies revealed a poorly differentiated carcinoma. A positron emission tomography with low dose CT scan was performed per protocol and revealed an intensely hypermetabolic tumor with no evidence for lymphatic disease or extra-thoracic spread. The patient underwent a surgical exploration and a right lower lobectomy with a thoracic lymphadenectomy. The pathology including immunohistochemical stains demonstrated a malignant melanoma with no lymph node involvement. A physical examination including ophthalmic, mucosal, and skin examinations revealed no evidence for an extra-thoracic site of the disease. The patient had negative margins for resection and did not receive any adjuvant therapy and is alive and well with no evidence for recurrence 3 years after the resection.

show abstract

Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review

Cited by 22 publications

References 47 publications

Primary pulmonary malignant melanoma: Case report and literature review

Primary pulmonary malignant melanoma: Case report and literature review

The Combination of Radiotherapy with Pembrolizumab in the Treatment of Metastatic Melanoma Patients: a Systematic Review

Primary malignant melanoma of the lung: a case report of a rare tumor and review of the literature

Contact Info

Product

Resources

About